The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia
Overweight, Hyperlipidemia, Cardiovascular Diseases
About this trial
This is an interventional treatment trial for Overweight focused on measuring Schizophrenia, Schizoaffective disorder, Aripiprazole, Obese, Overweight, Heart Health, Antipsychotic, Heart Health Factors, Cardiovascular Health Indices, Cardiovascular health
Eligibility Criteria
Inclusion Criteria: Male and female subjects ages 18-65 years Outpatients and stable partial hospital patients Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of schizophrenia or schizoaffective disorder No psychiatric hospitalization in 30 days prior to study start Partially remitted patients with a PANSS score below 100 at screening Currently on a stable dose of only one antipsychotic for at least 30 days prior to study start Currently receiving a stable dose of all other psychotropic medications for at least 30 days prior to study start BMI greater than 26 Female patients of childbearing age must be using an acceptable method of birth control for at least 1 month prior to participation in the research study and continue for at least 4 weeks after the final study visit. Ability to provide informed consent. Exclusion Criteria: Mental retardation Current treatment with clozapine Currently enrolled in a weight management program or receiving pharmacological treatment for weight reduction Serious or unstable medical illness Female patients who are pregnant, lactating, or plan to become pregnant during the study period Concurrently receiving treatment with ketoconazole, quinidine, carbamazepine.
Sites / Locations
- Western Psychiatric Institute and Clinic of UPMC